Science

Apr 25, 2025, 13:27

Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: For patients receiving quad induction, MRD<10-5 was 29% (<10-6 15%) and 59% post-ASCT (<10-6 45%); ASCT lowered MRD >1 log in 69%; quad (vs. triplet) did not reduce effect of ASCT; reduction in most pronounced in high-risk patients.”

“Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy”

Authors: Susan Bal, Tylan Magnusson, Gayathri Ravi, Smith Giri, Kelly Godby, Binod Dhakal, Natalie Callander, Rebecca Silbermann, Bhagirathbhai Dholaria, Vishnu Reddy, Luciano Costa.

More posts featuring Robert Orlowski.

Bhagirathbhai Dholaria Binod Dhakal cancer Gayathri Ravi Kelly Godby Luciano Costa multiple myeloma Myeloma Paper of the Day Natalie Callander OncoDaily Oncology Rebecca Silbermann Robert Orlowski Smith Giri Susan Bal T-cell therapy Tylan Magnusson Vishnu Reddy

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot